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Abstract: Autophagy primarily works to counteract nutrient deprivation that is strongly engaged
during starvation and hypoxia, which happens in hypoperfusion. Nonetheless, autophagy is slightly
active even in baseline conditions, when it is useful to remove aged proteins and organelles. This is
critical when the mitochondria and/or proteins are damaged by toxic stimuli. In the present
review, we discuss to that extent the recruitment of autophagy is beneficial in counteracting brain
hypoperfusion or, vice-versa, its overactivity may per se be detrimental for cell survival. While
analyzing these opposite effects, it turns out that the autophagy activity is likely not to be simply
good or bad for cell survival, but its role varies depending on the timing and amount of autophagy
activation. This calls for the need for an appropriate autophagy tuning to guarantee a beneficial
effect on cell survival. Therefore, the present article draws a theoretical pattern of autophagy
activation, which is hypothesized to define the appropriate timing and intensity, which should
mirrors the duration and severity of brain hypoperfusion. The need for a fine tuning of the autophagy
activation may explain why confounding outcomes occur when autophagy is studied using a rather
simplistic approach.
Keywords: cerebral blood flow; hypoxia; starvation; brain ischemia; autophagy; mitophagy;
neurodegeneration
1. Introduction
Autophagy (ATG) and ubiquitin proteasome system (UPS) are recruited for protein and
organelle degradation within eukaryotic cells. It is commonly believed that ATG and UPS possess
distinct substrates and act independently from each other within segregated cell compartments.
While UPS degrades short-lived proteins, ATG clears long-lived proteins and cell organelles, such as
mitochondria, through their delivery to late endosomes and/or lysosomes [1]. A number of conditions
may be counteracted by the ATG activation, such as age-related telomere and genomic alterations,
loss of proteostasis, dysregulation of nutrient-sensing pathways, mitochondrial dysfunctions, limited
regenerative ability, and altered cell to cell communication [2–5].
ATG degrades the cell components to produce energy as a natural response to cell starvation [6].
However, apart from extreme conditions, ATG is slightly active even in baseline cell physiology,
in order to guarantee the turnover of various cell components, thus avoiding the accumulation of
aged proteins or altered organelles. ATG machinery consists of a variety of membrane structures,
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which organize to form vesicles, where abnormal material is segregated and delivered to lysosomal
degradation. Three distinct ATG mechanisms are described, (i) macro-ATG, (ii) micro-ATG, and
(iii) chaperon-mediated ATG (CMA) (Figure 1).
Macro-ATG consists of autophagosomes. In the initiation phase, a double membrane-bound
phagophore gems from the endoplasmic reticulum (ER) and/or mitochondria; during the elongation
phase an immature autophagosome appears as an open membrane structure, named late phagophore,
where the ubiquitin-bound complex starts to be hosted. Furthermore, the ceiling of the vesicle
generates the mature autophagosome, a vesicle compartment, which includes a volume of normally
electron-dense cytosol. A variety of ubiquitin-dependent mechanisms shuttle altered substrates within
the autophagosome, thus increasing its electron-density.
During its progression, the autophagosome is driven along microtubules to merge with lysosomes,
forming the autophagolysosome, which contains a variety of enzymes [7–10]. Each ATG phase
is characterized by specific ATG markers, which bind to the membrane structures allowing for
deciphering the specific step within the ATG flux [11] (Figure 1A).
Micro-ATG differs from macro-ATG as small volumes of cytosol are directly enwrapped into
lysosomes [12]. This may occur through the enwrapping of cytosolic proteins in the lysosome
(membrane invagination or membrane protrusion); alternatively, cytosolic proteins are delivered
through the endosomal sorting complexes required for transport (ESCRT) once bound to chaperonine
Hsc70 [13,14] (Figure 1B). In contrast, CMA works through the molecular interaction of chaperones
with a lysosome receptor called lysosome-associated membrane protein-2 (LAMP-2), which allows a
receptor-mediated translocation into lysosomes of specifically tagged proteins [15] (Figure 1C).
Only macro-autophagy requires a previous ubiquitination of the substrates. When ATG removes
the mitochondria, the process is named mitophagy. Mitophagy is driven by the expression of
mitochondrial PINK1 (PTEN induced putative kinase 1), which recruits parkin within the altered
mitochondria [16]. Here, parkin promotes the binding of mitochondrial proteins to ubiquitin [17,18]
in order to be shuttled to the autophagosome or a nascent phagophore. At least three mitochondrial
proteins (mitofusin 1, mitofusin 2, and voltage-dependent anion-selective channel protein 1) undergo
parkin-dependent ubiquitination [19]. The mitochondrial proteins BNIP3 (Bcl2/adenovirus E1B 19 kDa
interacting protein 3) and BNIP3L/NIX (BNIP3 like), as well as the ATG receptor optineurin, are also
key for mitophagy. These proteins drive the mitochondria towards the autophagosome through the
binding of LC3 (microtubule-associated protein 1 light chain 3, MAP LC3-I) [20,21].
The alteration of ATG occurs during aging and in most age-related neurodegenerative disorders,
including Parkinson’s (PD) and Alzheimer’s disease (AD), leads to the accumulation of damaged
organelles and unfolded/misfolded proteins [2,3,6,22–25].
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Figure 1. The autophagy (ATG) clearing pathway. (A) Macro-ATG follows the activation of the 
autophagy initiation complex, named the ATG1 or Unc-51 like autophagy activating kinase (ULK) 
(Unc-51 like autophagy activating kinase) complex. This leads to the phagophore, an incomplete 
double-membrane structure, which gems from the mitochondrial or endoplasmic reticulum 
carrying Atg14 and vacuolar membrane protein 1 (VMP1). The ULK/ATG1 complex phosphorylates 
Atg14, allowing the recruitment of beclin 1 from bcl2 on the phagophore membrane. Beclin 1 binds 
to phosphatidylinositol-3-kinase class III (PI3K-III)/VPS34, forming the active complex PI3K-III, 
which produces a focal increase of phosphatidylinositol-3-phosphate (PI3P). This leads to the 
followng: (i) the Atg9-mediated recruitment of endosomes and multivesicular bodies, and the (ii) 
induction of ubiquitin-like reactions. These consist of the formation of the Atg5/Atg12/Atg16 
complex; or the assembly of the E1-like Atg7-mediated and the E2-like Atg3-mediated conjugation 
of LC3 to the phosphatidyletanolamine (PE), thus forming LC3-II (also called LC3 lipidation). 
Meanwhile, the late phagophore folds in order to enwrap the aged or damaged cell components, 
Figure 1. The autophagy (ATG) clearing pathway. (A) Macro-ATG follows the activation of the
autophagy initiation complex, named the ATG1 or Unc-51 like autophagy ctivating kinase (ULK)
(Unc-51 like autophagy activating kinase) complex. This leads to the phagophore, an incomplete
double-membrane structure, which gems from the mitochondrial or endoplasmic reticulum carrying
Atg14 and vacuolar membrane protein 1 (VMP1). The ULK/ATG1 complex phosphorylates Atg14,
allowing the recruitment of beclin 1 from bcl2 on the phagophore membrane. Beclin 1 binds to
phosphatidylinositol-3-kinase class III (PI3K-III)/VPS34, forming the active complex PI3K-III, which
produces a focal increase of phosp atidylinositol-3-phosphate (PI3P). This leads to the followng:
(i) the Atg9-mediated recruitment of endosomes and multivesicular bodies, and the (ii) induction
of ubiquitin-like reactions. These consist of the formation of the Atg5/Atg12/Atg16 complex;
or the assembly of the E1-like Atg7-mediated and the E2-like Atg3-mediated conjugation of LC3
to the phosphatidyletanolamine (PE), thus forming LC3-II (also called LC3 lipidation). Meanwhile,
the late phagophore folds in order to enwrap the aged or damaged cell components, such as the
ubiquitinated mitochondria and p62-bound poly-ubiquitinated proteins, which are sequestered within
a mature autophagosome. The fusion between the autophagosome with the lysosome involves
proteins belonging to the soluble N-ethylmaleimide sensitive factor attachment protein receptors
(SNARE) complex. (B) Micro-ATG is traditionally described as a direct transport of several substrates
into lysosomes for degradation; recently, it has been associated with the delivery of cargoes to late
endosomes/multivesicular bodies. This latter process is dependent from ESCTR and Hsc70 proteins.
(C) Chaperone-mediated ATG is a chaperone-mediated binding of specific substrates, which are
delivered to the lysosomes through a lysosomal receptor, LAMP-2. Solid arrow: main step, Dotted
arrow: molecule/vesicle trafficking.
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2. The Autophagy Pathway as a Hot Topic in Brain Hypoperfusion/Ischemic Research
Research on brain hypoperfusion has recently been increasing exponentially [26–28]. In fact,
differing from stroke, which causes sudden brain damage, chronic brain hypoperfusion (CBH) is a
slight and smoldering insult, produced by a moderate though persistent reduction in blood supply.
This allows neural cells to organize adaptive responses, which might compensate cell functions for
prolonged time intervals. This phase may last a variable time interval, depending on the severity of
the hypoperfusion. In detail, brain hypoperfusion indicates a condition of reduced cerebral blood
flow (CBF), which can even be long-lasting, and for this reason we usually refer to the term of
CBH. In the early stage, CBH may be asymptomatic, although cognitive/executive impairment may
occur, depending on the duration and severity of hypoperfusion, and the age of the subjects [28,29].
For instance, a mild-to-moderate reduction of CBF is common during aging and primarily affects the
cerebral cortex and basal forebrain [30–35]. When it surpasses a critical threshold, hypoperfusion is
critical for cell homeostasis [36,37], and it is associated with a decline in the cerebral metabolic rate
for O2 (CMRO2) and glucose (CMRGl) [38–41]. If protracted over time, brain hypoperfusion causes a
loss of energy and may produce neurological symptoms, often featuring cognitive impairment [27,42].
In line with this, CBH contributes to the key mechanisms generating vascular dementia [27], and it is a
major risk factor for cognitive impairment [27,43–46].
It is generally assumed that in CBH, the reduction of CBF is moderate and may last for several
years, and is asymptomatic at first, but progressively damages brain tissue. In contrast, brain
ischemia is a sudden symptomatic acute event. When the term cerebral ischemia is used, it implies
a severe occlusion of blood vessels, which develops suddenly and may recover clinically, such
as in a transient ischemic attack or leading to cerebral infarction or sudden death, as it occurs
in ischemic stroke [47]. Cerebral ischemia can be classified into three types, thrombotic, embolic,
and hemodynamic, according to its etiology [48], and into two types, focal and global ischemia,
based on the extent of the ischemic area [49]. During the maturation of irreversible ischemic brain
damage, there is a necrotic area surrounded by ‘area penumbra’, where the surviving cells develop
a number of alterations, which may be considered reminiscent of neurodegeneration though in a
condensed time interval [50]. To remark such a condition, the term acute neurodegeneration can
be used. On the other hand, CBH does not possess such a clear-cut pathological zoning, being
a quite homogeneous region, which slowly develops cytopathological alterations in a longer time
interval. Within this time frame, compensatory mechanisms concur with the deleterious deficit in
the blood supply of O2 and nutrients to determine a pathological area, which markedly differs from
that occurring following brain ischemia. Nonetheless, the reduction of cerebral oxygen supply is a
common determinant of both brain ischemia and CBH. Hypoxia can also occur without a reduction of
CBF, through other mechanisms such as reduced blood oxygenation, occurring in acute lung injury,
or a decreased oxygen transport in anemia. Among the variety of molecular mechanisms, which
may be involved in producing the tissue alterations following brain hypoperfusion/ischemia, it is
worth mentioning a number of changes affecting the small cerebral vessels both in structure and
density, with concomitant alterations in the blood brain barrier (BBB) integrity and impairment of the
neurovascular unit [51–55]. When CBH occurs naturally or during experimental conditions, the BBB is
altered [56–58] and neurovascular coupling is depressed. This is associated with cognitive impairment
and neuropathology, mainly in the hippocampus [59–61]. This is concomitant with the accumulation of
proteins such as β-amyloid and phospho-tau [62–69]. This confirms how CBH may trigger a cascade,
which leads to neuronal degeneration [26]. The accumulation of pathological proteins involved in
Alzheimer’s disease results, even following brain ischemia. In this respect, Pluta’s lab found that
the amyloid protein precursor increases after the transient ischemia in both experimental animals
and humans [70,71]. The defective proteolytic clearance of β-amyloid peptide due to the impaired
ATG is found to be involved in extracellular amyloid deposition, thus contributing to Alzheimer’s
disease pathogenesis [51]. Remarkably, the dysregulation of ATG genes following brain ischemia
was found concomitantly with significant alterations in the expression of the amyloid precursor
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protein, secretases, as well as the presenilin 1 and 2 genes [72–75]. Moreover, the accumulation of the
amyloid protein precursor correlates with decreased expression of caspase 3 [70,71], and the β-amyloid
peptide has been found to potentiate the tau protein phosphorylation [76]. Overall, these findings
suggest that the dysregulation of ATG- and apoptosis-related genes found in the post-ischemic brains
of rats may enhance the ischemia-induced accumulation of Alzheimer-related proteins [74,75,77].
This strengthens the role of hypoperfusion/ischemia in the pathological protein deposition, leading to
neurodegenerative dementia.
Being a molecular pathway, which is promptly activated upon starvation, oxidative stress, and
hypoxia, ATG is now attracting much interest in ischemia/hypoperfusion research [74,75]. In this
respect, it is well-known that ATG is markedly increased during the reperfusion phase, which follows
an ischemic insult [78,79]. Furthermore, the authentic functional significance of this increased ATG
activity is still under debate, and contradictory data are reported concerning its beneficial or detrimental
effects [80–83]. ATG proteins and vacuoles increase concomitantly with the apoptotic markers within
dying neurons. This supports the hypothesis for a detrimental role of ATG in post-ischemic cell
death [80,84–87].
A genetic analysis of the specific ATG and apoptosis markers was carried out in rats by Pluta’s
lab [74,75], following ischemia in medial temporal lobe and specifically within hippocampal CA1.
These researchers found significant alterations of the expression of specific ATG-, mitophagy-, and
apoptosis-related genes [74,75]. In particular, these findings suggest that the removal of damaged
mitochondria by mitophagy and apoptosis are responsible for the neuronal death in the post-ischemic
brain [75]. The involvement of ATG in endothelial damage leading to the impairment of BBB integrity
during cerebral ischemia is still controversial and it is worth being further investigated [55]. On the
other hand, during the post-ischemic reperfusion phase, ATG inhibition (i.e., by the constitutive
activation of mammalian target of rapamycin (mTOR), administration of the ATG inhibitors, and Atg7
knockdown) increases the neuronal damage and cognitive impairment. This suggests a protective role
of ATG during ischemia-induced brain damage [78,88–90]. In fact, the enhancement of ATG during
post-ischemic reperfusion or before inducing a ischemic insult (the so-called ‘ATG pre-conditioning’),
decreases the neuronal damage and reduces the neurological deficits [78,81,91–99].
CBH is much less investigated than ischemia. This is likely to depend on the smoldering clinical
impact offered suddenly by CBH compared with stroke. Only a few manuscripts are available dealing
with ATG and CBH, which does not allow for one to get a solid opinion whether it is protective or
deleterious [67,86,100–103]. Therefore, the present review is thought to clarify the state of the art in
such a quickly growing topic. In keeping with this, a big discrepancy exists between the amount of
investigations about ATG in acute cerebral ischemia [104,105] and CBH [26,67,86,100–103]. These latter
studies involve human patients and experimental models, which are reported in Table 1 [29,106–109].
It is important to emphasize that the choice of the appropriate experimental model and the quality of
the experimental design are key in order to reproduce a long-lasting reduction of CBF, such as in CBH,
or the more severe and sudden arrest of blood flow, such as in cerebral ischemia [110]. The experimental
models of brain hypoperfusion/ischemia consist of a reduction of CBF, achieved by the mono- or
bi-lateral occlusion of large cerebral arteries, thus resulting in a reduction of the blood flow mainly
affecting the brain cortex and hippocampus [110]. The type, number, and duration of the cerebral vessel
occlusion may determine the severity of the hypoperfusion. For instance, the model of two vessel
occlusion, consisting in the bilateral common carotid artery occlusion, is performed so as to produce a
mild reduction of CBF, according with CBH [29,106,111–115]. A more severe reduction of CBF, such as
that occurring in cerebral ischemia, may be produced by increasing the number of vessels occlusion.
For instance, the models of three or four vessel occlusions, such as the permanent bilateral occlusion of
the vertebral arteries, followed by the transient bilateral occlusion of the carotid arteries [116], or the
permanent occlusion of the middle cerebral artery, allows one to study the ischemic injury produced
by a sudden and consistent reduction of CBF [117–119]. On the other hand, the vascular anatomy
among mammals shows variations between species and even strains, with significant species-specific
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differences in the number of arterial collaterals, upon which the capacity to restore the blood flow
after vessel occlusion depends [120]. For instance, to produce global brain ischemia in rats or mice,
it is necessary to limit the blood flow in almost three or four arteries that supply the brain (namely,
carotid and vertebral arteries), or to reduce the systemic arterial pressure concomitantly with the
bilateral occlusion of the common carotid arteries [121,122]. In contrast, the bilateral occlusion of the
common carotid arteries (two vessel occlusion model) is able to produce global cerebral ischemia in
gerbils [123–125]. On the other hand, oxygen–glucose deprivation (OGD) is widely in vitro as a model
for cerebral ischemia to elucidate cellular and molecular mechanisms [109,126]. By analyzing these
models, a strong increase of ATG is consistently evident in both in vivo and in vitro. Interestingly,
considering the in vivo models of CBH, several studies show the occurrence of a wide temporal gap
between the ATG activation and the occurrence of cell death [103,127]. In fact, while ATG increases
immediately after the induction of brain hypoperfusion, cell death appears several weeks after CBH
induction [106]. During this phase, the cell metabolism is expected to be modified in order to cope
with the mutated nutrient supplies. A description of the main signaling pathways involved in these
CBH-induced metabolic changes may help to comprehend the scenario where ATG is activated in the
course of CBH.
Table 1. Experimental models of brain hypoperfusion/ischemia.
IN VIVO





Subcortical white matter lesions, and cortical
and hippocampal damage [106,107]
1VO:
MCCAo Mouse No hippocampal damage at seven days [108]
3VO:
BCCAo + MVAo Rat Severe cortical and hippocampal lesions [29]
IN VITRO





Glucose-free medium under a deoxygenated
atmosphere (hypoxic chamber) [109]
BCCAo—bilateral common carotid artery occlusion; MCCAo—monolateral common carotid artery occlusion;
MVAo—monolateral vertebral artery occlusion; OGD—oxygen–glucose deprivation VO—vessel occlusion.
2.1. Effects of Chronic Brain Hypoperfusion on ATG Activity
In the experimental model of CBH, the reduction of CBF is variable, depending on the specific
model and time interval at which it is measured [29,106]. For example, in a two vessel occlusion (2VO)
rat model, one week after the induction of CBH, the blood flow is reduced to roughly 30% within the
isocortex and 20% within the hippocampus, compared with intact rats [106]. The reduction of O2 and
nutrient supply causes a drop in the ATP levels and an increase of the reactive oxygen species (ROS).
The main cell pathways, which are triggered under CBH, are schematized in Figure 2.
Hypoxia and starvation accompany CBH and induce substantial changes in cell metabolism.
Decreased ATP levels increase the AMP/ATP ratio, which immediately activates the AMP activated
protein kinase (AMPK), a sensor of energy status of the cell [128,129]. The AMPK activity is also
increased by glucose starvation, with a mechanism, which involves the activation of the stress-induced
p53, sestrin 1, and sestrin 2 proteins [130]. Following the ROS-induced DNA double-strand breaks,
the nuclear ataxia-telengiectasia-mutated (ATM) kinase triggers a phosphorylation cascade, which
leads to an increase in the expression and cytosolic translocation of p53 [131], which in turn activates
AMPK by promoting its phosphorylation via the liver B1 kinase (LKB1) [129,132,133]. Moreover, the
ROS-dependent oxidation of cytosolic ATM causes its dimerization and the activation of AMPK [131].
The activation of AMPK stimulates ATG through inhibiting the mammalian target of rapamycin
(mTOR) (Figure 2). In this way, as mTOR inhibits ATG, CBH is expected to increase the ATG activity.
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is phosphorylated by several kinases, such as LKB1. Glucose deprivation increases p53, which 
stimulates the transcription of sestrin 1/sestrin 2 proteins, which, in turn, enhance the AMPK 
activation. Reactive oxygen species (ROS)-induced DNA damage increases the ataxia-telengiectasia-
mutated (ATM) activity, thus leading to increased p53 and REDD1 transcription. Upon oxidation by 
ROS, cytosolic ATM forms homodimers and activates AMPK by phosphorylation. CBH-induced 
calcium overload activate AMPK through calcium calmodulin-dependent kinases. AMPK inhibits 
mammalian target of rapamycin (mTOR) by acting on the Tsc2 protein. Tsc2 is part of the Tsc1/Tsc2 
complex, which converts the guanosine triphosphate (GTP) to guanosine diphosphate (GDP)-bound 
Rheb, which causes the inhibition of mTOR. In particular, AMPK phosphorylates Tsc2 at two sites, 
thus enhancing the ability of the Tsc1/Tsc2 complex to block Rheb-dependent mTOR activation. 
Finally, mTOR inhibition leads to ATG activation. The hypoxia-induced Akt pathway stimulates 
mTOR by inhibiting Tsc2. This occurs through Akt-dependent phosphorylation of Tsc2, thus 
inducing its dissociation from the complex Tsc1/Tsc2. This stabilizes Rheb to activate mTOR, 
thereby inhibiting ATG. The activation of Akt also triggers a phosphorylation cascade, producing 
various effects. A key protein targeted by Akt is the transcription factor cyclic AMP-responsive 
element binding protein (CREB), which induces the expression of genes related to cell growth and 
survival, such as brain derived neurotrophic factor (BDNF) and the anti-apoptotic protein bcl2. 
Moreover, Akt increases the expression of the alpha subunit of the transcription factor HIF-1, which 
is essential for hypoxia-inducible factor-1 (HIF-1) transcriptional activity. In turn, HIF-1 regulates 
the transcription of the genes related to anaerobic metabolism, thus promoting the shift towards the 
glycolytic metabolism. CBH-induced hypoxia and starvation also activate ATG throughout 
mechanisms that do not involve mTOR. The hypoxia-induced HIF-1 increases the expression BNIP3, 
which, via beclin 1, promotes ATG. An increased amount of beclin1 occurs through the c-Jun N-
terminal kinase (JNK) pathway under starvation and oxidative stress. Red arrow: increased 
activity/levels, Blue arrow: decreased activity/levels, Grey arrow: transition. 
Figure 2. The main metabolic pathways triggered by chronic brain hypoperfusion (CBH). Hypoxia
and starvation occurring during CBH activate several cell pathways. The AMP activated protein
kinase (AMPK) pathway is strongly activated during CBH. Increased AMP binds to AMPK, which
is phosphorylated by several kinases, such as LKB1. Glucose deprivation increases p53, which
stimulates the transcription of sestrin 1/sestrin 2 proteins, which, in turn, enhance the AMPK activation.
Reactive oxygen species (ROS)-induced DNA damage increases the ataxia-telengiectasia-mutated
(ATM) activity, thus leading to increased p53 and REDD1 transcription. Upon oxidation by ROS,
cytosolic ATM forms ho odimers and activates AMPK by phosphorylation. CBH-induced calcium
overload activate AMPK through calcium calmodulin-dependent kinases. AMPK inhibits mammalian
target of rapamycin (mTOR) by acting on the Tsc2 protein. Tsc2 is part of the Tsc1/Tsc2 complex, which
converts the guanosine triphosphate (GTP) to guanosine diphosphate (GDP)-bound Rheb, which causes
t inhibition of mTOR. In particular, AMPK phosphorylates Tsc2 at two sites, thus enhancing the
ability of the Tsc1/Tsc2 complex to block Rheb-de endent mTOR activation. Finally, mTOR inhibition
leads to ATG activation. The hypoxia-induced Akt pat way stimulat s mTOR by inhibiting Tsc2.
This occurs t rough Akt-dependent phosp orylation of Tsc2, thus inducing its dissociation from the
complex Tsc1/T c2. This stabilizes Rheb to activate mTOR, there y inhibiting ATG. The activation
of Akt also tr ggers a phosphorylation cascade, pr ducing various effects. A key protein targeted by
Akt is the transcription factor cyclic AMP-responsive eleme t b nding protein (CREB), which induc s
the expressio of gen s related to cell growth and survival, uch as brain d rive neurotrophic factor
(BDNF) and the anti- poptotic prot in bcl2. Moreover, Akt increases the expression of he alpha su unit
of the transcription f ctor HIF-1, which is essential for hypoxia-inducible factor-1 (HIF-1) transcriptional
activity. In tu n, HIF-1 regulates the transcription of the genes re ated to anaerobic metabolism, thus
promoting the shif toward the glyc lytic metabolism. CBH-induced hypoxia and s arvation also
activate ATG throughout mechanisms that do not involve mTOR. The hypoxia-induced HIF-1 increases
the expres ion BNIP3, which, via beclin 1, promotes ATG. An increased amount of becli 1 occurs
through the c-Jun N-ter inal kinase (JNK) pathway under starvatio and oxidative stress. Red arrow:
increased activity/levels, Blue rrow: decre sed activity/levels, Gr y arrow: transition.
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mTOR is a conserved serine/threonine kinase that phosphorylates several substrates involved
in protein translation [134]. The activity of mTOR is regulated by a variety of signals, in particular,
mTOR-dependent protein synthesis depends on the energy and nutrients’ availability, and for hypoxia,
in baseline conditions, the mTOR activity tunes essential pathways for the cell growth and proliferation
(protein and nucleotide synthesis, lipogenesis) [135], whereas in the conditions of hypoxia, the glucose
and amino acid deprivation mTOR activity is inhibited [135–137].
AMPK inhibits mTOR by phosphorylating Tsc2 (tuberose sclerosis complex 2) [138–140] (Figure 2).
The inhibition of mTOR through Tsc2 is also produced by the regulation of development and DNA
damage response 1 (REDD1) protein, which is induced by hypoxia, via a mechanism involving
increased ATM [136,141] (Figure 2). The hypoxia and increased ROS levels induce the activation of the
Akt pathway, which phosphorylates the substrates involved in cell growth and survival [142]. Among
these, the cyclic AMP-responsive element binding protein (CREB) is involved in this hypoxic-induced
increased expression of protective molecules, such as brain derived neurotrophic factor (BDNF) and
bcl2 [91,143–147]. Moreover, Akt inhibits Tsc2, leading to mTOR activation and ATG inhibition [83,139]
(Figure 2). Therefore, in hypoxic/ischemic conditions, ATG activity is oppositely modulated by the
AMPK and Akt pathways through mTOR [148], which in turn, may determine per se the inhibition of
ATG via different mechanisms [83,149]. Moreover, CBH induces ATG through mTOR-independent
mechanisms. For instance, hypoxia and ROS, either directly or through Akt activation, increase the
levels of hypoxia-inducible factor-1 (HIF-1) [83,150–152], which stimulates gene transcription in order
to promote anaerobic metabolism [153]. In fact, the shift from an oxidative to glycolytic metabolism
guarantees at least a few ATP production during CBH [154] (Figure 2). Moreover, HIF-1 induces ATG
by increasing the BNIP3 protein, which increases the levels of the beclin 1/VPS34 complex to initiate
the ATG process [155] (Figure 2). A similar mechanism is shared by the c-Jun N-terminal kinase (JNK)
signaling [156–158] (Figure 2).
Mitochondria are the organelles primarily affected during hypoxia. Several master regulators of
the cell energy status, involving the HIF-alpha and AMPK, are found to determine the dramatic changes
in the mitochondrial energy metabolism in order to promote glycolysis [159]. In this condition, the
mitochondrial respiratory chain is markedly reduced, leading to metabolic uncoupling, reduced ATP,
and a massive increase in ROS levels [160] (Figure 3). Dysfunctional mitochondria exhibit a depolarized
membrane potential, which causes the inversion of calcium pumps and cytosolic calcium overload. The
depolarized mitochondria are removed by ATG through the PINK1/parkin-dependent mitophagy [17,18].
In turn, the intracellular calcium concentration activates several calcium-sensitive kinases, which
activate AMPK and then stimulates the AMPK-ULK-dependent mitophagy [129,161,162]. These
conditions also promote the activation of Nrf2 (NF-E2-related factor 2)/SKN1 protein, which promotes
the transcription of several genes involved in mitochondrial biogenesis [21]. Moreover, HIF-1 induces
the mitochondrial removal by up-regulating the expression of BNIP3 [21,163] (Figure 3).
Interestingly, AMPK increases the mitochondrial number by stimulating the fission-dependent
mitochondria duplication. In fact, AMPK phosphorylates the mitochondrial fission factor (MFF),
which promotes the recruitment of dynamin related protein-1 (DRP-1). This localizes on the
outer mitochondrial membrane, where it stimulates the mitochondrial fission [164,165] (Figure 3).
Differently from mitochondria biogenesis, mitochondrial fission is a rapid, energy saving process,
which allows damaged mitochondria to duplicate. The mitochondria generated by fission differ
regarding the membrane potential. In fact, one of the two daughter’s mitochondria is depolarized.
This allows damaged molecules to dilute differently in the two novel organelles, where the depolarized
mitochondria are quickly removed by mitophagy. Recent studies report the occurrence of the cell-to-cell
transmission of mitochondrial signaling (‘mitokines’), as well as the intercellular propagation of
mitochondria through the tunneling nanotube, which may represent a way to widely diffuse the
mitochondrial injury following hypoxia and oxidative stress [159]. Other compensatory responses
are induced, including inflammation, unfolded protein response (UPR), and apoptosis. All of these
increase under the hypoxic/ischemic insult [99,152,158,166–169]. In fact, hypoxia induces apoptosis
Int. J. Mol. Sci. 2018, 19, 2756 9 of 24
and/or ATG. For instance, the JNK-dependent regulation of the bax-bcl2-beclin1 complex plays a dual
role. In fact, JNK promotes th eATG activation through beclin 1, while it promotes apoptosis, inducing
bax, and then caspase 9 and 3 activation [158,170,171]. This scenario is a paradigm for the need of a
fine tuning, where slight dose differences may shift the balance between ATG and apoptosis during
CBH in opposite directions [86,172]. Moreover, the induction of ATG needs to be finely registered in
order to sort protective effects rather than producing ATG-induced neuronal damage.Int. J. M l. Sci. 2018, 19, x  9 of 24 
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Figure 3. CBH induces mitophagy. Hypoxia heavily affects the mitochondria by interfering with the
mitochondrial respiratory chain, and by dramatically decreasing the mitochondrial ATP production.
In these conditions, dysfunctional mitochondria massively produce ROS to be released into the
cytosol. Moreover, a loss of the mitochondrial membrane potential occurs. Thus, a mitochondrial
depolarized membrane causes an inversion of calcium pumps and cytosolic calcium overload.
The intracellular calcium activates the calcium-sensitive kinases, which activate AMPK. These calcium
dependent kinases contribute to the activation of the Nrf2/SKN1 protein, which promotes the
genes involved in mitochondrial biogenesis. The depolarized mitochondria are rapidly removed by
ATG through the PINK1/parkin-dependent mitophagy. This is also induced by hypoxia-induced
HIF-1. In fact, HIF-1 increases the BNIP3 protein, which acts on the mitochondrial membrane
as a mitophagy receptor through its binding to LC3-II. Finally, the removal of dysfunctional
mitochondria by mitophagy is also induced by AMPK-dependent ULK activation. Interestingly,
the AMPK activation also promotes mitochondrial fission by enhancing the mitochondrial fission
factor (MFF)activity. CAMKKbeta—calcium/calmodulin dependent protein kinase kinase beta;
CAMKII—calcium/calmodulin dependent protein kinase type II. Red arrow: increased activity/levels,
Blue arrow: decreased activity/levels.
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2.2. Autophagy Modulation During Brain Hypoperfusion
Most of the pharmacological treatments known to be protective against neuronal damage
induced by CBH are supposed to act as ATG inhibitors [86,103,128,173–177]. In particular, although
characterized by different mechanisms of action, most reports emphasize the suppression of the ATG
activation occurring in CBH [86,101,102,174–177]. This line of evidence suggests that the micro-balance
working for ATG in CBH is shifted towards a deleterious effect of ATG on neuronal survival. This is
the case of the L-calcium channel inhibitor nimodipine [103,128], the gamma-aminobutyric acid type
B (GABAB) agonist baclofen [86], the anti-inflammatory and anti-oxidant agent lipoxin A4 methyl
ester [173,174], the active alkaloid extract from Leonurus cardiaca leonurine [175], the endogenous
cannabinoid system modulators WIN55,212-2 and URB597 [101,178], and the neurohypophyseal
hormone arginine vasopressin [102]. In contrast, other studies provide evidence that in CBH ATG
activation is protective for cell survival, whereas a detrimental effect is associated with the ATG
reduction [67,100,102]. In fact, in experimental models of ischemia/hypoperfusion LC3-II levels are
reduced, mTOR is activated and an increased expression and accumulation of the phosphorylated tau
protein is documented [67,179–181]. In vitro experiments carried out in OGD conditions show that
the classic ATG inducer rapamycin decreases cell death, while the ATG inhibitor 3-methyladenine
(3-MA) and the lysosomal inhibitor MHY1485 increase cell death [182]. Thus, the dual (protective and
detrimental) role of ATG remains unsolved so far.
In an effort to improve the analysis carried out on limited data regarding the effect of ATG in
CBH, a validation of the methods used to monitor the ATG status is analyzed here. Most of the
studies postulating the detrimental effects of ATG in CBH are grounded merely on the assay of ATG
markers such as LC3 [86,101,103,127,174,183]. However, when the ATG flux is not progressing, LC3
is increased rather than suppressed, but ATG is not effective. In fact, when the ATG progression
was specifically examined, a reduction rather than an increase of ATG was evident in CBH [100].
This is exemplified by two studies both reporting the neuroprotective effects of the L-type calcium
channel antagonist nimodipine. This compound was reported to attenuate the excess of ATG in a rat
model of CBH [103,127]. In fact, nimodipine rescued the spatial memory deficit and alleviated the
neuronal damage in the cortex and hippocampal CA1 at two and four weeks after the induction of
CBH [103]. An extended analysis up to eight weeks confirmed a long-lasting, the protective effect
of nimodipine on cognitive functions and CA1 hippocampal neurons after induction of CBH [127].
Both of the studies correlated this neuroprotective effect with ATG inhibition, as nimodipine decreased
the LC3-II levels [127] and the LC3-II/LC3-I ratio [103]. However, apart from measuring the ATG
markers, these studies did not provide a direct assessment of the ATG flux, which is mandatory when
inferring the number of markers as a measure of the ATG status.
Other studies show that the chronic treatment with URB597 (URB) carried out in a two vessel
occlusion (2VO) rat model of CBH is protective against cognitive dysfunctions and hippocampal
neuronal loss [101,178]. This was evaluated 12 weeks after the induction of hypoperfusion [101,178].
The CBH-induced neuronal damage was evaluated by the amount of the cell loss within the
hippocampal CA1, which was significantly rescued by the URB post-treatment. Even this effect
was associated with a reduction of the ATG markers, which were related to the mTOR activation.
Unexpectedly, when the classic ATG inhibitor 3-MA was co-administered with URB, no further
protection was observed [101]. In contrast, 3-MA worsened the cell damage [101]. Unfortunately, these
authors failed to provide data measuring the effects produced by 3-MA on CBH [101]. In contrast with
previous findings, a beneficial effect of a prolonged ATG activation in CBH was investigated in rats,
where the molecular mechanisms underlying the neuroprotective effects of the arginine-vasopressin
(AVP) neurohypophyseal hormone were documented [102]. This effect was produced through the
stimulation of hippocampal vasopressin 1 (V1) receptors. In particular, the V1 activation enhances
the CBH-induced ATG activation, as witnessed by the increased LC3-II/LC3-I and beclin 1 levels,
as well as the LC3-II-positive puncta detected within the hippocampal neurons [102]. Moreover,
in this study, an ultrastructural investigation showed that the autophagolysosomes were increased [102].
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This latter finding, referred to four weeks after the induction of hypoperfusion, suggesting that the V1
stimulation was effective in promoting the ATG flux, which was instead impaired by CBH.
Evidence for the involvement of various ATG-related miRNAs in the pathophysiology of
hypoxia-induced cell damage is increasing [184–187]. A careful analysis at the transmission electron
microscopy allowed for correlating the specific intracellular ATG structures with the progression
of the ATG flux during CBH [100]. This approach was integrated with immunocytochemical and
immunoblotting investigations. This study demonstrates that during CBH, there is an increase of
miRNA27a, which produces an inhibition of the ATG flux [100]. In fact, two weeks after CBH, when the
increased expression of miRNA27a takes place, a fall in the ATG status occurred. This was evidenced
by the profuse accumulation of the ATG vacuoles and increased p62 levels, along with high levels of
LC3-II. Therefore, despite high levels of the classic ATG marker LC3-II, the ATG flux was depressed.
In particular, miRNA27a reduces the level of the lysosomal receptor LAMP-2, thus suggesting a specific
inhibition of the CMA-dependent lysosomal degradation [100].
The role of ATG in CBH remains very controversial [100–102,183]. This might depend on different
experimental conditions in which the ATG pathway is evaluated in different studies, and the methods
used to investigate ATG. In particular, in most studies, the ATG status was investigated only using
the immunohistochemistry and/or immunoblotting assay for the ATG markers. No evidence was
provided concerning the ultrastructural analysis of the ATG structures and the dynamics of ATG
(for instance, through the measurement of the ATG substrates and/or the downstream molecules of
the ATG inhibitor mTOR). In fact, the ATG markers do not necessarily relate to the ATG activity. As a
paradigm is the case of the increased ATG markers occurring when the stagnant ATG vacuoles engulf
the cells, as the ATG flux slows down [188]. This is not a pure theoretical detail, because a protective
ATG should be an ongoing progressive flux [189]. In this respect, when the ATG flux was evaluated,
a protective effect of ATG was found in CBH [100–102,182].
2.3. A Dynamic Hypothesis of the ATG Response in Chronic Brain Hypoperfusion
In the lack of a unitary view concerning which mechanisms are actually neuroprotective in CBH,
here, we provide a hypothesis that tempts to reconcile the experimental data on the ATG flux during
CBH with the CBH-induced metabolic changes, at different time intervals (Figure 4). Briefly, CBH
represents a border-line condition, which put the viability of the neurons and glia at risk, without
representing a frank toxic insult. In fact, a chronic reduction of CBF produces only mild-to-moderate
hypoxia and starvation, compared with that occurring in stroke. However, in CBH, these conditions
are long-lasting, and they may persist silent for years before producing brain damage. A mild but
persistent hypoxic insult allows the cell to organize adaptive responses in order to compensate such
critical conditions.
In our analysis, we keep the following two temporal phases during CBH distinct: (i) early phase,
which starts soon after the onset of CBH, which lasts up to about one week (Figure 4A); (ii) late phase,
when the cell metabolism is irreversibly impaired and the cell lost compensatory mechanisms lasting
several weeks after the onset of CBH (Figure 4B).
In the early phase, the energy and hypoxia sensor systems are the main cellular pathways, which
are promptly activated soon after the onset of brain hypoperfusion, leading to a switch from the
oxidative-dependent aerobic metabolism to the glycolytic (anaerobic) metabolism. At the same time,
in order to save energy and make cells less dependent on circulating substrates, the anabolic reactions,
which for allow cell growth and proliferation, are markedly reduced, whereas the catabolism is
enhanced. Within this context, early ATG activation induced by CBH should be interpreted as an
immediate protective response (Figure 4A). Despite experimental models of CBH, the ATG activation
is not investigated during the early hours of the induction of hypoperfusion, occurrence of increased
ATG markers beclin 1, and LC3-II is widely documented within 24–48 h after a cerebral ischemic
insult [74,81,190], thus suggesting a similar cellular response in CBH.




Figure 4. A dynamic model for the protective role of ATG in CBH. (A) The early phase of CBH
is characterized by a sudden increase of the ATG activation. In this phase, the O2 and nutrients
deprivation rapidly induce ATG, which is effective in the removal of altered cell components. Oxidative
stress damages mitochondria, which are suddenly cleared by mitophagy. In this early phase of CBH,
the ATG flux is normally ongoing and the ATG activation is key in delaying the cell death. (B) In the
late phase of CBH, the protracted hypoxia, the severe energy deprivation, along with a further increase
in the ROS levels, seriously worsen the cell functions. In these conditions, ATG further increased,
but the broad cargoes overwhelm the ATG capacity, leading to a defective cell clearance. In particular,
damaged mitochondria accumulate within the cytosol and become by themselves a source of additional
ROS. Moreover, altered mitochondria release cytochrome c and other pro-apoptotic proteins. On the
other hand, in this late phase of CBH, apoptosis is induced by a variety of stimuli. In particular,
the apoptosis is triggered by the severe hypoxia, associated with mitochondrial damage and oxidative
DNA injury. In this condition, a concomitant strong increase of both the ATG and apoptosis occurs.
Moreover, the apoptosis and ATG are strictly interconnected and reciprocally regulated by several
mechanisms. Therefore, the late CBH features as accumulation of ATG vacuoles, because of the relented
ATG flux and increased apoptotic cell death. Red arrow: increased activity/levels, Blue straight arrow:
modulatory effect, Blue curved arrow: intensity of ATG flux.
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The exacerbation of cell damage obtained when ATG has been inhibited prior to, or immediately
after the onset of ischemia/chronic hypoperfusion provides compelling evidence of ATG as being
protective in delaying cell death in hypoperfusion [81,101,182]. On the other hand, long-lasting brain
hypoperfusion leads to an unbalance cell homeostasis. In fact, when the reduction of blood flow
is chronic, energy deficiency becomes progressively more severe, and so is oxidative stress, which
damages the cell components. In this late phase, the ATG activity is further enhanced in an attempt
to counteract the increasing levels of accumulating substrates. This corresponds to the so-called
‘excess’ of ATG, characterized by the highest levels of the ATG markers LC3-II and beclin 1, which
are extensively documented in CBH [86,100,102,103,127]. In these conditions, apoptotic cell death
is reported in CBH concomitantly with increased ATG markers [86], and treatments that reduce the
ATG activation are found to be protective against a CBH-induced increase in the caspase level and/or
neuronal death [86,103,127]. These findings suggest that ATG is responsible for the delayed cell injury
observed in CBH.
However, an analysis of ATG flux at this late time interval (up to 12 weeks) reveals occurrence of
defective ATG process. This may be explained by considering that, when hypoperfusion is long-lasting,
the levels of the ATG substrates overwhelm the intrinsic capacity of the ATG machinery. As a matter
of fact, a reduction of the autophagolysosomes and lysosomes compared with the autophagosomes
witnesses for an engulfment of ATG, which occurs late during CBH [100]. This happens despite the
high levels of LC3-II, which may disguise the investigator by suggesting an increased ATG activity,
which does not take progress [86,100,103,127,183]. In fact, when the ATG substrates overwhelm the
activity of the ATG pathway, then the elevated ATG markers co-exist along with a delayed progression
of ATG; this appears morphologically as stagnant giant ATG vacuoles within the cytosol (Figure 4B).
Such a chronic condition, which is likely to feature the late phase of CBH, is characterized by a complex
cross-talk between ATG and apoptosis. In this respect, increasing evidence indicates that apoptosis
and ATG are strictly interconnected, and multiple cellular pathways contribute to reciprocally regulate
these events according to a fine balance [115,158,191–193]. For instance, it is documented that in
hypoxic conditions, when mitochondrial damage and oxidative DNA injury become consistent, both
ATG and apoptosis are triggered [115,191]. On the other hand, the apoptotic and ATG machineries
share some regulatory signaling, which allows for switching from one to the other, depending on the
metabolic state of the cells. In this respect, we reported the peculiar role of the beclin 1/bcl2 interplay
in regulating ATG and apoptosis, thus allowing for turning ATG on or off, depending on the energy
stores [158,171,194–196].
Independently from the pathway that is involved, in late CBH, a relented ATG, which causes
an accumulation of damaged cell components, occurs together with an enhanced apoptosis, which
depends on increasing pro-apoptotic stimuli. These mainly consist of damaged mitochondria, which
are no longer removed by impaired ATG, and triggers the apoptotic cascade mainly through oxidative
stress [115]. Therefore, even in the absence of a frank ATG suppression, later, in the CBH cell, death
may derive from a loss of an effective ATG, which is bound to enhanced apoptosis.
In line with this, a recent review by Wolf et al. (2018) suggests that impaired ATG flux and
lysosomal function, leading to increased autophagosome formation without progression towards
autophagolysosomes, is critical in producing cell injury associated with ischemic insult [105].
Remarkably, these authors propose the term ‘autosis’, first coined by Liu et al. (2013) to
indicate a form of ATG cell death with “unique morphological features, including increased
autophagosomes/autolysosomes . . . , which occurs during treatment with autophagy-inducing
peptides, starvation, and cerebral hypoxia–ischemia” [197]. This is supported by a number of studies
dealing with ATG in acute brain injury, which consistently show that the treatments that enhance ATG
by stimulating the ATG flux reduce the rate of autophagosome formation and are neuroprotective in
experimental models of acute brain injury.
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3. Conclusions
The present review represents an effort to disambiguate the role ATG in CBH compared with
ischemia, as it appears from the recent literature. We show that ATG is markedly induced by CBH,
which in fact produces an early and persistent increase in the ATG markers. However, the ATG flux,
which reflects the actual ATG activity, exhibits a different time course, being increased at early time
intervals after the onset of hypoperfusion, but being decreased when the hypoperfusion is long-lasting.
In this respect, the increased amount of ATG vacuoles engulfing the cytosol of dying neurons might
represent an epiphenomenon, which accompanies cell death in the late phase of CBH. A similar role of
ATG, though in a condensed time interval, appears to occur in brain ischemia.
This latter point sheds a new light on the significance of the ATG activation during CBH, which
dynamically develops through time, and might be susceptible to different modulations at different
time intervals.
We propose that the correct tuning of ATG during CBH should be finely tuned in time and
intensity, so as to produce beneficial effects in CBH.
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